| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| rho-Associated Kinases | 73 | 2026 | 162 | 12.160 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 67 | 2026 | 403 | 9.490 |
Why?
|
| Endothelium, Vascular | 71 | 2020 | 440 | 7.780 |
Why?
|
| Cardiovascular Diseases | 25 | 2022 | 802 | 3.370 |
Why?
|
| Stroke | 30 | 2019 | 1154 | 3.210 |
Why?
|
| Neovascularization, Physiologic | 14 | 2026 | 146 | 3.000 |
Why?
|
| Nitric Oxide Synthase Type III | 39 | 2020 | 84 | 2.780 |
Why?
|
| Brain Ischemia | 15 | 2020 | 416 | 2.670 |
Why?
|
| Nitric Oxide | 33 | 2018 | 286 | 2.650 |
Why?
|
| Nitric Oxide Synthase | 30 | 2005 | 124 | 2.490 |
Why?
|
| Endothelial Cells | 20 | 2026 | 500 | 2.420 |
Why?
|
| Cardiomegaly | 12 | 2016 | 114 | 2.410 |
Why?
|
| Leukocytes | 18 | 2016 | 212 | 2.180 |
Why?
|
| Animals | 148 | 2026 | 28894 | 1.870 |
Why?
|
| Signal Transduction | 43 | 2026 | 3620 | 1.840 |
Why?
|
| Muscle, Smooth, Vascular | 16 | 2014 | 234 | 1.830 |
Why?
|
| Cholesterol | 21 | 2022 | 373 | 1.750 |
Why?
|
| Simvastatin | 17 | 2019 | 106 | 1.690 |
Why?
|
| Atherosclerosis | 17 | 2017 | 266 | 1.630 |
Why?
|
| Phosphatidylinositol 3-Kinases | 11 | 2006 | 285 | 1.600 |
Why?
|
| RGS Proteins | 2 | 2026 | 22 | 1.600 |
Why?
|
| Protein Kinase Inhibitors | 14 | 2020 | 640 | 1.570 |
Why?
|
| Mice | 86 | 2026 | 12698 | 1.530 |
Why?
|
| Cardiovascular System | 6 | 2017 | 52 | 1.510 |
Why?
|
| Dyslipidemias | 4 | 2022 | 114 | 1.450 |
Why?
|
| Cells, Cultured | 54 | 2026 | 2855 | 1.450 |
Why?
|
| Mice, Knockout | 39 | 2026 | 2207 | 1.370 |
Why?
|
| Enzyme Inhibitors | 21 | 2019 | 642 | 1.360 |
Why?
|
| Receptor, Notch1 | 7 | 2011 | 106 | 1.340 |
Why?
|
| Proto-Oncogene Proteins c-akt | 16 | 2020 | 370 | 1.290 |
Why?
|
| rac1 GTP-Binding Protein | 10 | 2013 | 47 | 1.250 |
Why?
|
| Myocytes, Cardiac | 10 | 2024 | 328 | 1.170 |
Why?
|
| Disease Models, Animal | 24 | 2024 | 2572 | 1.110 |
Why?
|
| Humans | 166 | 2026 | 98080 | 1.110 |
Why?
|
| Anticholesteremic Agents | 6 | 2011 | 164 | 1.100 |
Why?
|
| Ischemia | 11 | 2026 | 262 | 1.070 |
Why?
|
| Hypercholesterolemia | 7 | 2010 | 161 | 1.050 |
Why?
|
| Coronary Artery Disease | 9 | 2019 | 387 | 1.040 |
Why?
|
| Transcription Factors | 9 | 2012 | 1717 | 1.020 |
Why?
|
| Carotid Arteries | 5 | 2020 | 132 | 1.010 |
Why?
|
| Enzyme Activation | 23 | 2015 | 679 | 1.000 |
Why?
|
| Vascular Stiffness | 4 | 2021 | 29 | 0.980 |
Why?
|
| Neovascularization, Pathologic | 6 | 2016 | 356 | 0.980 |
Why?
|
| Anti-Inflammatory Agents | 5 | 2022 | 358 | 0.970 |
Why?
|
| Hemorrhage | 4 | 2017 | 299 | 0.960 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 14 | 2019 | 403 | 0.930 |
Why?
|
| Transcription, Genetic | 14 | 2006 | 1133 | 0.910 |
Why?
|
| Cattle | 26 | 2011 | 397 | 0.910 |
Why?
|
| Myocardial Infarction | 7 | 2025 | 396 | 0.900 |
Why?
|
| 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine | 11 | 2019 | 36 | 0.900 |
Why?
|
| Mice, Inbred C57BL | 34 | 2026 | 3598 | 0.900 |
Why?
|
| Genetic Pleiotropy | 2 | 2017 | 33 | 0.900 |
Why?
|
| Cholesterol, LDL | 9 | 2023 | 250 | 0.890 |
Why?
|
| Molecular Targeted Therapy | 2 | 2020 | 321 | 0.870 |
Why?
|
| NF-kappa B | 15 | 2010 | 423 | 0.840 |
Why?
|
| Antioxidants | 8 | 2005 | 236 | 0.830 |
Why?
|
| rho GTP-Binding Proteins | 8 | 2013 | 58 | 0.820 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2017 | 707 | 0.820 |
Why?
|
| Vascular Endothelial Growth Factor A | 11 | 2026 | 400 | 0.790 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2012 | 682 | 0.770 |
Why?
|
| Hemangioma, Cavernous, Central Nervous System | 6 | 2026 | 278 | 0.770 |
Why?
|
| Vascular Diseases | 5 | 2016 | 120 | 0.770 |
Why?
|
| Heart Failure | 8 | 2024 | 1491 | 0.740 |
Why?
|
| Phosphorylation | 16 | 2026 | 1145 | 0.740 |
Why?
|
| Hindlimb | 6 | 2026 | 98 | 0.740 |
Why?
|
| GTP-Binding Proteins | 9 | 2008 | 150 | 0.730 |
Why?
|
| Cell Movement | 12 | 2026 | 814 | 0.730 |
Why?
|
| Heptanoic Acids | 6 | 2013 | 72 | 0.730 |
Why?
|
| Pyrroles | 6 | 2013 | 165 | 0.690 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 10 | 2013 | 58 | 0.690 |
Why?
|
| Angiotensin II | 8 | 2014 | 98 | 0.690 |
Why?
|
| Male | 80 | 2026 | 47076 | 0.680 |
Why?
|
| Receptors, Estrogen | 5 | 2003 | 428 | 0.660 |
Why?
|
| Ventricular Remodeling | 2 | 2024 | 108 | 0.660 |
Why?
|
| rhoA GTP-Binding Protein | 10 | 2019 | 90 | 0.650 |
Why?
|
| Thrombosis | 2 | 2023 | 318 | 0.650 |
Why?
|
| Up-Regulation | 13 | 2018 | 743 | 0.650 |
Why?
|
| Estrogens | 6 | 2003 | 201 | 0.650 |
Why?
|
| Inflammation | 7 | 2016 | 1120 | 0.640 |
Why?
|
| Biomarkers | 12 | 2022 | 2020 | 0.630 |
Why?
|
| Dipyridamole | 3 | 2008 | 12 | 0.610 |
Why?
|
| Gene Expression Regulation, Enzymologic | 9 | 2015 | 215 | 0.600 |
Why?
|
| Phosphotransferases (Alcohol Group Acceptor) | 3 | 2009 | 64 | 0.590 |
Why?
|
| Apoptosis | 13 | 2026 | 1752 | 0.590 |
Why?
|
| Muscle Proteins | 2 | 2012 | 131 | 0.580 |
Why?
|
| 8,11,14-Eicosatrienoic Acid | 5 | 2004 | 11 | 0.580 |
Why?
|
| Aorta | 17 | 2014 | 275 | 0.570 |
Why?
|
| Tunica Intima | 2 | 2009 | 61 | 0.560 |
Why?
|
| Neuroprotection | 1 | 2018 | 6 | 0.540 |
Why?
|
| RNA, Messenger | 24 | 2015 | 2063 | 0.540 |
Why?
|
| Cellular Senescence | 2 | 2009 | 110 | 0.540 |
Why?
|
| rac GTP-Binding Proteins | 4 | 2013 | 25 | 0.530 |
Why?
|
| Coronary Angiography | 3 | 2016 | 237 | 0.530 |
Why?
|
| Cyclic GMP | 3 | 2024 | 63 | 0.510 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 3 | 2006 | 46 | 0.500 |
Why?
|
| Cerebrovascular Circulation | 9 | 2008 | 239 | 0.500 |
Why?
|
| Drug Design | 3 | 2015 | 135 | 0.490 |
Why?
|
| Cell Cycle Proteins | 3 | 2008 | 419 | 0.490 |
Why?
|
| Hypertension | 7 | 2019 | 778 | 0.490 |
Why?
|
| Polyisoprenyl Phosphates | 5 | 2006 | 5 | 0.480 |
Why?
|
| Cardiomyopathy, Dilated | 3 | 2007 | 91 | 0.480 |
Why?
|
| Angiopoietin-2 | 1 | 2016 | 23 | 0.480 |
Why?
|
| Vasodilation | 11 | 2019 | 91 | 0.480 |
Why?
|
| Estradiol | 3 | 2024 | 268 | 0.470 |
Why?
|
| Angina Pectoris | 2 | 2015 | 18 | 0.470 |
Why?
|
| Troponin T | 1 | 2016 | 42 | 0.460 |
Why?
|
| Acute Coronary Syndrome | 3 | 2015 | 31 | 0.460 |
Why?
|
| Oxidative Stress | 9 | 2013 | 489 | 0.450 |
Why?
|
| Down-Regulation | 6 | 2008 | 529 | 0.450 |
Why?
|
| Bronchial Hyperreactivity | 2 | 2015 | 73 | 0.440 |
Why?
|
| LIM-Homeodomain Proteins | 2 | 2012 | 24 | 0.440 |
Why?
|
| Bone Marrow Cells | 3 | 2011 | 269 | 0.440 |
Why?
|
| Neuropeptides | 3 | 2013 | 113 | 0.440 |
Why?
|
| Myocardium | 5 | 2025 | 578 | 0.430 |
Why?
|
| Arteriosclerosis | 6 | 2004 | 107 | 0.430 |
Why?
|
| Gene Expression Regulation | 12 | 2013 | 2023 | 0.430 |
Why?
|
| Nerve Tissue Proteins | 4 | 2011 | 512 | 0.430 |
Why?
|
| Coronary Disease | 4 | 2007 | 227 | 0.420 |
Why?
|
| Hypolipidemic Agents | 3 | 2023 | 101 | 0.420 |
Why?
|
| Oxygenases | 4 | 2004 | 17 | 0.420 |
Why?
|
| Fibrosis | 5 | 2020 | 234 | 0.410 |
Why?
|
| Hypersensitivity | 2 | 2017 | 166 | 0.410 |
Why?
|
| Cytochrome P-450 Enzyme System | 4 | 2004 | 77 | 0.410 |
Why?
|
| GTP Phosphohydrolases | 7 | 2015 | 83 | 0.410 |
Why?
|
| Superoxides | 5 | 2007 | 76 | 0.400 |
Why?
|
| NADPH Oxidases | 5 | 2007 | 87 | 0.400 |
Why?
|
| Mice, Transgenic | 11 | 2020 | 1604 | 0.400 |
Why?
|
| Blotting, Western | 13 | 2012 | 780 | 0.400 |
Why?
|
| Rats | 16 | 2010 | 4071 | 0.390 |
Why?
|
| Treatment Outcome | 15 | 2026 | 9711 | 0.390 |
Why?
|
| Percutaneous Coronary Intervention | 1 | 2014 | 81 | 0.390 |
Why?
|
| Obesity | 2 | 2012 | 1061 | 0.390 |
Why?
|
| Female | 49 | 2026 | 51536 | 0.390 |
Why?
|
| Genes, MHC Class II | 2 | 2004 | 28 | 0.390 |
Why?
|
| Atrial Fibrillation | 1 | 2019 | 461 | 0.380 |
Why?
|
| Blood-Brain Barrier | 3 | 2021 | 86 | 0.380 |
Why?
|
| Blood Pressure | 9 | 2019 | 910 | 0.380 |
Why?
|
| Reperfusion Injury | 2 | 2012 | 148 | 0.380 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2012 | 220 | 0.380 |
Why?
|
| Dose-Response Relationship, Drug | 16 | 2015 | 1950 | 0.370 |
Why?
|
| Cyclic AMP | 4 | 2008 | 277 | 0.370 |
Why?
|
| I-kappa B Proteins | 5 | 2000 | 47 | 0.370 |
Why?
|
| Reactive Oxygen Species | 3 | 2011 | 525 | 0.360 |
Why?
|
| Coronary Vasospasm | 1 | 2012 | 6 | 0.360 |
Why?
|
| Ischemic Attack, Transient | 3 | 2007 | 195 | 0.360 |
Why?
|
| Risk Factors | 13 | 2026 | 6233 | 0.360 |
Why?
|
| Heart-Assist Devices | 2 | 2017 | 916 | 0.350 |
Why?
|
| Middle Aged | 36 | 2026 | 29428 | 0.350 |
Why?
|
| Cell Adhesion | 11 | 2016 | 419 | 0.350 |
Why?
|
| Lung | 2 | 2018 | 1407 | 0.350 |
Why?
|
| Nitric Oxide Synthase Type II | 13 | 2006 | 92 | 0.350 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2012 | 312 | 0.350 |
Why?
|
| Idiopathic Pulmonary Fibrosis | 1 | 2015 | 238 | 0.350 |
Why?
|
| Mitochondria, Muscle | 1 | 2011 | 24 | 0.350 |
Why?
|
| Repressor Proteins | 4 | 2009 | 447 | 0.350 |
Why?
|
| Preoperative Care | 1 | 2014 | 418 | 0.350 |
Why?
|
| Regional Blood Flow | 7 | 2008 | 194 | 0.340 |
Why?
|
| Insulin Resistance | 2 | 2012 | 391 | 0.340 |
Why?
|
| Oxazepines | 1 | 2011 | 5 | 0.340 |
Why?
|
| Farnesyl-Diphosphate Farnesyltransferase | 1 | 2011 | 5 | 0.340 |
Why?
|
| Aged | 27 | 2025 | 21758 | 0.330 |
Why?
|
| Tissue Plasminogen Activator | 3 | 2005 | 180 | 0.330 |
Why?
|
| Vasculitis | 2 | 2008 | 42 | 0.330 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2011 | 62 | 0.320 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 5 | 2024 | 75 | 0.320 |
Why?
|
| Diet, High-Fat | 1 | 2012 | 143 | 0.320 |
Why?
|
| MAP Kinase Kinase Kinase 5 | 2 | 2007 | 3 | 0.320 |
Why?
|
| Hydroxymethylglutaryl CoA Reductases | 2 | 2002 | 17 | 0.320 |
Why?
|
| Isoenzymes | 3 | 2020 | 272 | 0.320 |
Why?
|
| Protein Isoforms | 4 | 2021 | 303 | 0.320 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2026 | 82 | 0.310 |
Why?
|
| Piperidines | 1 | 2011 | 172 | 0.310 |
Why?
|
| Cell Line | 11 | 2020 | 2483 | 0.300 |
Why?
|
| Lipoproteins, LDL | 7 | 2012 | 87 | 0.300 |
Why?
|
| Blood Vessels | 2 | 2009 | 92 | 0.300 |
Why?
|
| Regeneration | 1 | 2010 | 162 | 0.300 |
Why?
|
| Muscle, Skeletal | 2 | 2011 | 521 | 0.300 |
Why?
|
| Cell Proliferation | 7 | 2014 | 1790 | 0.290 |
Why?
|
| Pyrimidines | 2 | 2008 | 413 | 0.290 |
Why?
|
| Hemangioma, Cavernous | 2 | 2019 | 66 | 0.290 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2013 | 312 | 0.290 |
Why?
|
| Genome, Human | 1 | 2014 | 832 | 0.290 |
Why?
|
| Cerebral Hemorrhage | 2 | 2025 | 377 | 0.290 |
Why?
|
| Nerve Growth Factors | 1 | 2009 | 54 | 0.290 |
Why?
|
| Microtubule-Associated Proteins | 2 | 2000 | 186 | 0.290 |
Why?
|
| Lovastatin | 5 | 2001 | 28 | 0.290 |
Why?
|
| Promoter Regions, Genetic | 10 | 2004 | 977 | 0.280 |
Why?
|
| Vasodilator Agents | 9 | 2019 | 134 | 0.280 |
Why?
|
| Fluorobenzenes | 1 | 2008 | 34 | 0.280 |
Why?
|
| Azetidines | 1 | 2008 | 38 | 0.280 |
Why?
|
| Estrogen Receptor alpha | 3 | 2024 | 159 | 0.280 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 92 | 0.280 |
Why?
|
| Myocytes, Smooth Muscle | 5 | 2014 | 135 | 0.280 |
Why?
|
| RNA Stability | 5 | 2008 | 98 | 0.270 |
Why?
|
| Drug Therapy, Combination | 3 | 2022 | 764 | 0.270 |
Why?
|
| Endothelium | 2 | 2009 | 63 | 0.270 |
Why?
|
| Oxidation-Reduction | 6 | 2008 | 419 | 0.270 |
Why?
|
| Actinin | 1 | 2008 | 19 | 0.270 |
Why?
|
| Time Factors | 14 | 2026 | 5567 | 0.270 |
Why?
|
| Phosphodiesterase Inhibitors | 1 | 2008 | 30 | 0.270 |
Why?
|
| Heart | 3 | 2012 | 527 | 0.270 |
Why?
|
| Nuclear Proteins | 2 | 2011 | 750 | 0.260 |
Why?
|
| Calmodulin | 1 | 2008 | 50 | 0.260 |
Why?
|
| Hyperaldosteronism | 2 | 2019 | 14 | 0.260 |
Why?
|
| Receptors, Bradykinin | 3 | 1997 | 11 | 0.260 |
Why?
|
| Protein Prenylation | 6 | 2005 | 10 | 0.260 |
Why?
|
| Genetic Variation | 1 | 2014 | 1445 | 0.260 |
Why?
|
| Clinical Trials as Topic | 6 | 2017 | 1129 | 0.250 |
Why?
|
| Stem Cells | 2 | 2011 | 396 | 0.250 |
Why?
|
| Brain | 7 | 2021 | 2430 | 0.250 |
Why?
|
| Cell Adhesion Molecules | 5 | 2001 | 184 | 0.250 |
Why?
|
| Cerebral Infarction | 4 | 2018 | 72 | 0.250 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2026 | 16 | 0.250 |
Why?
|
| Immunity, Innate | 1 | 2010 | 481 | 0.240 |
Why?
|
| Insulin | 1 | 2012 | 1225 | 0.240 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2003 | 255 | 0.240 |
Why?
|
| Microfilament Proteins | 1 | 2008 | 211 | 0.240 |
Why?
|
| Adrenal Cortex Hormones | 3 | 2003 | 305 | 0.240 |
Why?
|
| Sulfonamides | 1 | 2008 | 351 | 0.240 |
Why?
|
| Mice, Mutant Strains | 5 | 2015 | 217 | 0.240 |
Why?
|
| Circadian Rhythm | 1 | 2008 | 295 | 0.240 |
Why?
|
| Saphenous Vein | 6 | 2006 | 61 | 0.240 |
Why?
|
| Metalloporphyrins | 2 | 2016 | 26 | 0.230 |
Why?
|
| Postoperative Complications | 2 | 2017 | 2681 | 0.230 |
Why?
|
| Receptors, Thyroid Hormone | 1 | 2006 | 158 | 0.230 |
Why?
|
| Metabolic Syndrome | 1 | 2007 | 125 | 0.230 |
Why?
|
| Carrier Proteins | 1 | 2009 | 667 | 0.230 |
Why?
|
| Hydrogen Peroxide | 3 | 2007 | 173 | 0.230 |
Why?
|
| Emergency Service, Hospital | 3 | 2021 | 634 | 0.230 |
Why?
|
| Cholesterol, HDL | 3 | 2016 | 173 | 0.230 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2006 | 95 | 0.220 |
Why?
|
| Animals, Newborn | 1 | 2006 | 524 | 0.220 |
Why?
|
| NG-Nitroarginine Methyl Ester | 6 | 2008 | 45 | 0.220 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2025 | 14 | 0.220 |
Why?
|
| Thrombin | 3 | 2017 | 60 | 0.220 |
Why?
|
| Cell Survival | 5 | 2013 | 1014 | 0.220 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2007 | 194 | 0.220 |
Why?
|
| Terpenes | 3 | 2010 | 18 | 0.220 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2018 | 58 | 0.220 |
Why?
|
| Rifabutin | 1 | 2004 | 3 | 0.220 |
Why?
|
| Patient Readmission | 2 | 2020 | 425 | 0.210 |
Why?
|
| Ovariectomy | 1 | 2024 | 94 | 0.210 |
Why?
|
| Carotid Stenosis | 1 | 2005 | 116 | 0.210 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2004 | 45 | 0.210 |
Why?
|
| Peptide Elongation Factor 1 | 2 | 2018 | 10 | 0.210 |
Why?
|
| Ventricular Function, Left | 2 | 2024 | 540 | 0.210 |
Why?
|
| Hyperglycemia | 1 | 2005 | 186 | 0.200 |
Why?
|
| Predictive Value of Tests | 6 | 2014 | 1782 | 0.200 |
Why?
|
| Thyroid Hormones | 1 | 2006 | 358 | 0.200 |
Why?
|
| Coculture Techniques | 4 | 2024 | 175 | 0.200 |
Why?
|
| Receptors, Cell Surface | 1 | 2005 | 291 | 0.200 |
Why?
|
| Cell Division | 5 | 2003 | 689 | 0.200 |
Why?
|
| Heart Function Tests | 1 | 2003 | 29 | 0.200 |
Why?
|
| Eicosanoids | 2 | 2004 | 18 | 0.200 |
Why?
|
| Inflammation Mediators | 3 | 2015 | 164 | 0.200 |
Why?
|
| Neuroprotective Agents | 6 | 2010 | 94 | 0.190 |
Why?
|
| Structure-Activity Relationship | 3 | 2015 | 425 | 0.190 |
Why?
|
| Dexamethasone | 2 | 2002 | 318 | 0.190 |
Why?
|
| Transfection | 6 | 2013 | 883 | 0.190 |
Why?
|
| Antihypertensive Agents | 3 | 2019 | 267 | 0.190 |
Why?
|
| Mutation | 4 | 2012 | 4392 | 0.190 |
Why?
|
| Naphthalenes | 1 | 2003 | 43 | 0.190 |
Why?
|
| Follow-Up Studies | 10 | 2026 | 4025 | 0.190 |
Why?
|
| Cell Cycle | 2 | 2001 | 518 | 0.190 |
Why?
|
| Risk Assessment | 5 | 2019 | 2585 | 0.190 |
Why?
|
| Ergosterol | 1 | 2002 | 3 | 0.190 |
Why?
|
| C-Reactive Protein | 4 | 2016 | 208 | 0.190 |
Why?
|
| Porins | 1 | 2002 | 25 | 0.190 |
Why?
|
| Anions | 1 | 2002 | 33 | 0.180 |
Why?
|
| Homeodomain Proteins | 1 | 2006 | 566 | 0.180 |
Why?
|
| Receptors, Glucocorticoid | 2 | 2003 | 145 | 0.180 |
Why?
|
| Raloxifene Hydrochloride | 1 | 2002 | 10 | 0.180 |
Why?
|
| Interferon-gamma | 2 | 2002 | 479 | 0.180 |
Why?
|
| Membrane Proteins | 3 | 2007 | 1285 | 0.180 |
Why?
|
| S-Nitrosoglutathione | 5 | 2003 | 10 | 0.180 |
Why?
|
| Nitroso Compounds | 5 | 2003 | 12 | 0.180 |
Why?
|
| Cytoplasm | 1 | 2002 | 276 | 0.180 |
Why?
|
| Case-Control Studies | 6 | 2017 | 1995 | 0.180 |
Why?
|
| Umbilical Veins | 3 | 2006 | 45 | 0.170 |
Why?
|
| Salicylates | 1 | 2001 | 25 | 0.170 |
Why?
|
| Pneumonia | 2 | 2015 | 195 | 0.170 |
Why?
|
| Mevalonic Acid | 5 | 2006 | 12 | 0.170 |
Why?
|
| Calcitriol | 1 | 2002 | 173 | 0.170 |
Why?
|
| Cardiotonic Agents | 1 | 2002 | 92 | 0.170 |
Why?
|
| Matrix Metalloproteinase 3 | 1 | 2021 | 11 | 0.170 |
Why?
|
| Bone Marrow Transplantation | 4 | 2012 | 286 | 0.170 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gs | 1 | 2001 | 24 | 0.170 |
Why?
|
| Sodium Salicylate | 1 | 2000 | 4 | 0.170 |
Why?
|
| Gene Expression | 4 | 2011 | 1320 | 0.160 |
Why?
|
| Prospective Studies | 6 | 2019 | 4823 | 0.160 |
Why?
|
| Amides | 3 | 2011 | 54 | 0.160 |
Why?
|
| Cyclins | 1 | 2000 | 80 | 0.160 |
Why?
|
| Double-Blind Method | 6 | 2025 | 1782 | 0.160 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2013 | 123 | 0.160 |
Why?
|
| Muscle Contraction | 5 | 2015 | 269 | 0.160 |
Why?
|
| Receptors, AMPA | 1 | 2020 | 72 | 0.160 |
Why?
|
| Nitroprusside | 4 | 2014 | 25 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2007 | 1012 | 0.160 |
Why?
|
| Office Visits | 1 | 2020 | 49 | 0.160 |
Why?
|
| Blotting, Northern | 5 | 2007 | 239 | 0.160 |
Why?
|
| Brachial Artery | 5 | 2019 | 37 | 0.160 |
Why?
|
| Interferon Regulatory Factors | 3 | 2020 | 76 | 0.150 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 212 | 0.150 |
Why?
|
| Community Health Workers | 1 | 2020 | 41 | 0.150 |
Why?
|
| Taiwan | 2 | 2012 | 27 | 0.150 |
Why?
|
| Germinal Center | 1 | 2020 | 66 | 0.150 |
Why?
|
| Cell Communication | 1 | 2001 | 222 | 0.150 |
Why?
|
| Pyridines | 4 | 2011 | 318 | 0.150 |
Why?
|
| DNA-Binding Proteins | 5 | 2001 | 1255 | 0.150 |
Why?
|
| Severity of Illness Index | 4 | 2013 | 2013 | 0.150 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 63 | 0.150 |
Why?
|
| Receptors, Notch | 3 | 2009 | 139 | 0.150 |
Why?
|
| Gene Deletion | 3 | 2017 | 353 | 0.150 |
Why?
|
| Prognosis | 8 | 2015 | 4116 | 0.150 |
Why?
|
| Drug Delivery Systems | 3 | 2011 | 200 | 0.150 |
Why?
|
| Rats, Sprague-Dawley | 5 | 2007 | 1255 | 0.150 |
Why?
|
| Polymorphism, Single Nucleotide | 3 | 2014 | 2558 | 0.150 |
Why?
|
| Sirolimus | 2 | 2012 | 182 | 0.150 |
Why?
|
| Fibroblasts | 2 | 2018 | 767 | 0.150 |
Why?
|
| Urban Population | 1 | 2020 | 246 | 0.140 |
Why?
|
| Rats, Wistar | 4 | 2004 | 304 | 0.140 |
Why?
|
| Goblet Cells | 3 | 2017 | 20 | 0.140 |
Why?
|
| Immunologic Factors | 2 | 2012 | 179 | 0.140 |
Why?
|
| Disease Susceptibility | 3 | 2009 | 226 | 0.140 |
Why?
|
| Botulinum Toxins | 1 | 1998 | 16 | 0.140 |
Why?
|
| Precipitin Tests | 3 | 2003 | 101 | 0.140 |
Why?
|
| Adult | 17 | 2026 | 29539 | 0.140 |
Why?
|
| Myosin-Light-Chain Phosphatase | 4 | 2013 | 9 | 0.140 |
Why?
|
| Bronchoalveolar Lavage Fluid | 3 | 2017 | 136 | 0.140 |
Why?
|
| Pre-Eclampsia | 1 | 2021 | 270 | 0.140 |
Why?
|
| Macrophages | 3 | 2012 | 643 | 0.140 |
Why?
|
| Mitochondria | 2 | 2016 | 650 | 0.140 |
Why?
|
| In Vitro Techniques | 5 | 2010 | 945 | 0.130 |
Why?
|
| Aspirin | 3 | 2007 | 169 | 0.130 |
Why?
|
| Models, Biological | 4 | 2012 | 1807 | 0.130 |
Why?
|
| Social Determinants of Health | 1 | 2019 | 132 | 0.130 |
Why?
|
| Intracranial Hemorrhages | 1 | 2019 | 138 | 0.130 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2008 | 98 | 0.130 |
Why?
|
| Arginine | 3 | 2008 | 143 | 0.130 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1997 | 18 | 0.130 |
Why?
|
| Actins | 4 | 2026 | 480 | 0.130 |
Why?
|
| Violence | 1 | 2019 | 164 | 0.130 |
Why?
|
| Amyloid Precursor Protein Secretases | 2 | 2009 | 99 | 0.130 |
Why?
|
| Protein Binding | 5 | 2012 | 1554 | 0.130 |
Why?
|
| Vascular Remodeling | 1 | 2017 | 24 | 0.130 |
Why?
|
| Hypoxia | 2 | 2005 | 699 | 0.130 |
Why?
|
| Coronary Vessels | 3 | 2013 | 178 | 0.130 |
Why?
|
| Nitric Oxide Donors | 2 | 2015 | 13 | 0.130 |
Why?
|
| Blood Platelets | 3 | 2017 | 153 | 0.130 |
Why?
|
| Escherichia coli Proteins | 1 | 1998 | 185 | 0.130 |
Why?
|
| RNA Processing, Post-Transcriptional | 1 | 1998 | 132 | 0.130 |
Why?
|
| Glutathione | 4 | 1997 | 108 | 0.120 |
Why?
|
| Caspase 3 | 3 | 2006 | 161 | 0.120 |
Why?
|
| Caspases | 3 | 2006 | 151 | 0.120 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2011 | 889 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 2 | 2013 | 412 | 0.120 |
Why?
|
| Peptide Fragments | 3 | 2012 | 480 | 0.120 |
Why?
|
| Ethanol | 1 | 1999 | 282 | 0.120 |
Why?
|
| T-Lymphocytes | 3 | 2012 | 1327 | 0.120 |
Why?
|
| Pandemics | 1 | 2022 | 916 | 0.120 |
Why?
|
| Fractals | 1 | 2016 | 41 | 0.120 |
Why?
|
| Triglycerides | 2 | 2008 | 233 | 0.120 |
Why?
|
| Pulmonary Fibrosis | 1 | 2018 | 158 | 0.120 |
Why?
|
| Kinetics | 4 | 2000 | 1476 | 0.120 |
Why?
|
| Cardiology | 1 | 2017 | 124 | 0.120 |
Why?
|
| Oxidants, Photochemical | 1 | 2015 | 1 | 0.120 |
Why?
|
| Binding Sites | 5 | 2006 | 1159 | 0.120 |
Why?
|
| Arteriovenous Malformations | 1 | 2016 | 55 | 0.110 |
Why?
|
| Ozone | 1 | 2015 | 12 | 0.110 |
Why?
|
| B-Lymphocytes | 1 | 2020 | 727 | 0.110 |
Why?
|
| Intercellular Adhesion Molecule-1 | 3 | 2008 | 77 | 0.110 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2012 | 62 | 0.110 |
Why?
|
| Mitochondrial Membrane Transport Proteins | 1 | 2015 | 11 | 0.110 |
Why?
|
| Analysis of Variance | 2 | 2009 | 889 | 0.110 |
Why?
|
| Isosorbide Dinitrate | 1 | 2015 | 2 | 0.110 |
Why?
|
| Respiratory Hypersensitivity | 1 | 2015 | 36 | 0.110 |
Why?
|
| Heart Diseases | 2 | 2010 | 268 | 0.110 |
Why?
|
| Lipid Metabolism | 2 | 2009 | 221 | 0.110 |
Why?
|
| Transforming Growth Factor beta | 1 | 1997 | 356 | 0.110 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 7389 | 0.110 |
Why?
|
| Capillary Permeability | 2 | 2018 | 133 | 0.110 |
Why?
|
| Reference Values | 2 | 2007 | 608 | 0.110 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2012 | 218 | 0.110 |
Why?
|
| Cytokines | 2 | 2015 | 889 | 0.100 |
Why?
|
| Cyclic GMP-Dependent Protein Kinases | 2 | 2024 | 17 | 0.100 |
Why?
|
| Molecular Sequence Data | 6 | 2014 | 2896 | 0.100 |
Why?
|
| Calcium Channel Blockers | 2 | 2011 | 118 | 0.100 |
Why?
|
| Quinolines | 2 | 2013 | 97 | 0.100 |
Why?
|
| Interleukin-17 | 2 | 2015 | 113 | 0.100 |
Why?
|
| Prenylation | 1 | 2013 | 3 | 0.100 |
Why?
|
| Proteins | 1 | 1999 | 804 | 0.100 |
Why?
|
| Platelet Aggregation | 2 | 2017 | 40 | 0.100 |
Why?
|
| Phenylephrine | 2 | 2006 | 30 | 0.100 |
Why?
|
| DNA | 4 | 2006 | 1274 | 0.100 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2017 | 502 | 0.100 |
Why?
|
| Vitamin D | 1 | 2016 | 286 | 0.100 |
Why?
|
| Receptor, TIE-2 | 2 | 2015 | 20 | 0.100 |
Why?
|
| Blood Flow Velocity | 3 | 2010 | 179 | 0.100 |
Why?
|
| Arginase | 1 | 2013 | 15 | 0.100 |
Why?
|
| Recombinant Proteins | 4 | 2021 | 993 | 0.100 |
Why?
|
| Cytosol | 2 | 2007 | 193 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2017 | 417 | 0.100 |
Why?
|
| Cognition | 1 | 2018 | 673 | 0.100 |
Why?
|
| Nitroglycerin | 4 | 2019 | 24 | 0.100 |
Why?
|
| Hemangiosarcoma | 1 | 2013 | 16 | 0.100 |
Why?
|
| Recurrence | 2 | 2026 | 1254 | 0.100 |
Why?
|
| Diabetic Angiopathies | 1 | 2013 | 40 | 0.100 |
Why?
|
| Sphingosine | 2 | 2010 | 73 | 0.100 |
Why?
|
| Smoking | 2 | 2010 | 674 | 0.100 |
Why?
|
| Protein Structure, Tertiary | 2 | 2006 | 731 | 0.100 |
Why?
|
| Plakophilins | 1 | 2012 | 4 | 0.090 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2013 | 76 | 0.090 |
Why?
|
| Peripheral Vascular Diseases | 1 | 2013 | 56 | 0.090 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1009 | 0.090 |
Why?
|
| Mesothelioma | 1 | 2016 | 346 | 0.090 |
Why?
|
| Femoral Artery | 2 | 2004 | 96 | 0.090 |
Why?
|
| Atrial Natriuretic Factor | 2 | 2003 | 38 | 0.090 |
Why?
|
| Arteries | 2 | 2011 | 171 | 0.090 |
Why?
|
| Interleukin-1 | 3 | 2006 | 72 | 0.090 |
Why?
|
| Retinal Vessels | 2 | 2026 | 53 | 0.090 |
Why?
|
| Adenoma | 1 | 2015 | 260 | 0.090 |
Why?
|
| Penis | 1 | 2013 | 65 | 0.090 |
Why?
|
| Stroke Volume | 4 | 2012 | 464 | 0.090 |
Why?
|
| Receptor, Notch3 | 2 | 2009 | 4 | 0.090 |
Why?
|
| Adherens Junctions | 1 | 2012 | 35 | 0.090 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1992 | 16 | 0.090 |
Why?
|
| Cross-Sectional Studies | 2 | 2016 | 2037 | 0.090 |
Why?
|
| Receptors, Neurotransmitter | 1 | 1992 | 24 | 0.090 |
Why?
|
| Bradykinin | 1 | 1992 | 45 | 0.090 |
Why?
|
| Survival Rate | 2 | 2008 | 2041 | 0.090 |
Why?
|
| RNA, Small Interfering | 3 | 2013 | 564 | 0.090 |
Why?
|
| Cell Differentiation | 4 | 2018 | 1646 | 0.090 |
Why?
|
| Citrulline | 1 | 2012 | 10 | 0.090 |
Why?
|
| Mice, Inbred C3H | 1 | 2012 | 370 | 0.090 |
Why?
|
| Oncogene Protein v-akt | 1 | 2012 | 21 | 0.090 |
Why?
|
| Spironolactone | 1 | 2011 | 13 | 0.090 |
Why?
|
| Mineralocorticoid Receptor Antagonists | 1 | 2011 | 20 | 0.090 |
Why?
|
| Protein Conformation | 1 | 2015 | 923 | 0.090 |
Why?
|
| Proadifen | 2 | 2002 | 2 | 0.090 |
Why?
|
| Ergonovine | 1 | 1991 | 2 | 0.090 |
Why?
|
| Uterine Hemorrhage | 1 | 1991 | 22 | 0.090 |
Why?
|
| Mesenteric Arteries | 1 | 2011 | 29 | 0.090 |
Why?
|
| Interleukin-5 | 1 | 2011 | 36 | 0.080 |
Why?
|
| Apolipoproteins E | 3 | 2010 | 139 | 0.080 |
Why?
|
| Neurites | 1 | 2011 | 38 | 0.080 |
Why?
|
| Transcriptional Activation | 2 | 2010 | 293 | 0.080 |
Why?
|
| Huntington Disease | 1 | 2011 | 36 | 0.080 |
Why?
|
| Chi-Square Distribution | 1 | 2012 | 360 | 0.080 |
Why?
|
| Interleukin-13 | 1 | 2011 | 42 | 0.080 |
Why?
|
| Platelet-Derived Growth Factor | 2 | 2002 | 65 | 0.080 |
Why?
|
| Vascular Resistance | 1 | 1991 | 98 | 0.080 |
Why?
|
| Glucose | 2 | 2012 | 704 | 0.080 |
Why?
|
| Neuroimmunomodulation | 1 | 2010 | 13 | 0.080 |
Why?
|
| Aortic Diseases | 2 | 2012 | 88 | 0.080 |
Why?
|
| Abortion, Spontaneous | 1 | 1991 | 74 | 0.080 |
Why?
|
| Homocysteine | 1 | 2010 | 31 | 0.080 |
Why?
|
| Propylene Glycols | 1 | 2010 | 30 | 0.080 |
Why?
|
| Corpus Striatum | 1 | 2011 | 83 | 0.080 |
Why?
|
| NF-KappaB Inhibitor alpha | 3 | 1999 | 38 | 0.080 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 839 | 0.080 |
Why?
|
| Eosinophils | 1 | 2011 | 196 | 0.080 |
Why?
|
| Respiratory Mechanics | 1 | 2011 | 109 | 0.080 |
Why?
|
| Oxygen | 1 | 1995 | 802 | 0.080 |
Why?
|
| cdc42 GTP-Binding Protein | 1 | 2010 | 12 | 0.080 |
Why?
|
| Muscle, Smooth | 2 | 2015 | 299 | 0.080 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2000 | 35 | 0.080 |
Why?
|
| Green Fluorescent Proteins | 1 | 2011 | 310 | 0.080 |
Why?
|
| Carotid Artery Injuries | 1 | 2010 | 22 | 0.080 |
Why?
|
| Myosins | 1 | 2010 | 89 | 0.080 |
Why?
|
| Cyclin-Dependent Kinases | 2 | 2000 | 43 | 0.080 |
Why?
|
| Ultrasonography | 5 | 2019 | 720 | 0.080 |
Why?
|
| Cell Nucleus | 2 | 2002 | 615 | 0.080 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 2 | 2008 | 47 | 0.080 |
Why?
|
| Interleukins | 1 | 2010 | 135 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2002 | 557 | 0.080 |
Why?
|
| Odds Ratio | 2 | 2013 | 726 | 0.080 |
Why?
|
| Cadherins | 1 | 2011 | 184 | 0.080 |
Why?
|
| Calcium | 2 | 2006 | 1196 | 0.080 |
Why?
|
| Immunoblotting | 3 | 2011 | 274 | 0.070 |
Why?
|
| COS Cells | 3 | 2008 | 163 | 0.070 |
Why?
|
| DNA, Complementary | 2 | 2003 | 380 | 0.070 |
Why?
|
| Drug Synergism | 2 | 2008 | 317 | 0.070 |
Why?
|
| Osteopontin | 2 | 2015 | 48 | 0.070 |
Why?
|
| KRIT1 Protein | 2 | 2019 | 62 | 0.070 |
Why?
|
| Annexin A5 | 1 | 2009 | 20 | 0.070 |
Why?
|
| Azepines | 1 | 2009 | 29 | 0.070 |
Why?
|
| Microarray Analysis | 1 | 2009 | 96 | 0.070 |
Why?
|
| Alanine | 1 | 2009 | 82 | 0.070 |
Why?
|
| Rosuvastatin Calcium | 1 | 2008 | 31 | 0.070 |
Why?
|
| Pravastatin | 2 | 2013 | 17 | 0.070 |
Why?
|
| Period Circadian Proteins | 1 | 2008 | 13 | 0.070 |
Why?
|
| Genotype | 4 | 2010 | 1888 | 0.070 |
Why?
|
| Ezetimibe | 1 | 2008 | 37 | 0.070 |
Why?
|
| Receptor, Bradykinin B2 | 1 | 2008 | 2 | 0.070 |
Why?
|
| Japan | 3 | 2015 | 303 | 0.070 |
Why?
|
| Tubulin | 1 | 2008 | 61 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 2 | 2006 | 122 | 0.070 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 2008 | 52 | 0.070 |
Why?
|
| Cationic Amino Acid Transporter 1 | 1 | 2008 | 1 | 0.070 |
Why?
|
| Cell Hypoxia | 2 | 2002 | 191 | 0.070 |
Why?
|
| Aminoquinolines | 1 | 2008 | 21 | 0.070 |
Why?
|
| Tertiary Care Centers | 2 | 2021 | 131 | 0.070 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2009 | 310 | 0.070 |
Why?
|
| Base Sequence | 5 | 2014 | 2222 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2019 | 201 | 0.070 |
Why?
|
| Wound Healing | 2 | 2012 | 384 | 0.070 |
Why?
|
| Guanosine Triphosphate | 2 | 1998 | 36 | 0.070 |
Why?
|
| Eating | 1 | 2009 | 164 | 0.070 |
Why?
|
| Chemotaxis | 1 | 2008 | 77 | 0.070 |
Why?
|
| Two-Hybrid System Techniques | 1 | 2008 | 55 | 0.070 |
Why?
|
| ras Proteins | 2 | 1999 | 137 | 0.070 |
Why?
|
| Monocytes | 3 | 2000 | 219 | 0.070 |
Why?
|
| Ultraviolet Rays | 1 | 2008 | 198 | 0.070 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2007 | 1 | 0.070 |
Why?
|
| Thioredoxin-Disulfide Reductase | 1 | 2007 | 2 | 0.070 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2007 | 2 | 0.070 |
Why?
|
| Laser-Doppler Flowmetry | 2 | 2006 | 19 | 0.070 |
Why?
|
| Neurons | 3 | 2011 | 1619 | 0.070 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gq-G11 | 1 | 2007 | 7 | 0.070 |
Why?
|
| Estrogen Receptor Modulators | 1 | 2007 | 10 | 0.070 |
Why?
|
| Sensitivity and Specificity | 1 | 2012 | 1945 | 0.070 |
Why?
|
| Thioredoxins | 1 | 2007 | 12 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2008 | 160 | 0.060 |
Why?
|
| Acetophenones | 1 | 2007 | 27 | 0.060 |
Why?
|
| Dicarboxylic Acids | 1 | 2007 | 24 | 0.060 |
Why?
|
| Drug Implants | 1 | 2007 | 36 | 0.060 |
Why?
|
| Body Mass Index | 2 | 2011 | 850 | 0.060 |
Why?
|
| Cell Size | 1 | 2007 | 71 | 0.060 |
Why?
|
| Brain Chemistry | 1 | 2007 | 110 | 0.060 |
Why?
|
| Ticlopidine | 1 | 2007 | 25 | 0.060 |
Why?
|
| Tetrazoles | 1 | 2007 | 23 | 0.060 |
Why?
|
| Models, Neurological | 1 | 2010 | 411 | 0.060 |
Why?
|
| Aldosterone | 2 | 2019 | 57 | 0.060 |
Why?
|
| Pulmonary Artery | 2 | 2002 | 342 | 0.060 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 1 | 2008 | 111 | 0.060 |
Why?
|
| Chromones | 1 | 2006 | 31 | 0.060 |
Why?
|
| Hemodynamics | 2 | 2008 | 747 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 1 | 1 | 2013 | 686 | 0.060 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2014 | 2555 | 0.060 |
Why?
|
| Lipopolysaccharides | 2 | 2006 | 313 | 0.060 |
Why?
|
| Retrospective Studies | 7 | 2020 | 10973 | 0.060 |
Why?
|
| Morpholines | 1 | 2006 | 67 | 0.060 |
Why?
|
| Dendritic Cells | 1 | 2011 | 552 | 0.060 |
Why?
|
| Drug Interactions | 1 | 2007 | 239 | 0.060 |
Why?
|
| Ankle Brachial Index | 2 | 2019 | 29 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2007 | 200 | 0.060 |
Why?
|
| Gingiva | 1 | 2006 | 7 | 0.060 |
Why?
|
| Androstadienes | 1 | 2006 | 71 | 0.060 |
Why?
|
| Nuclear Receptor Coactivator 3 | 1 | 2006 | 5 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2013 | 811 | 0.060 |
Why?
|
| GATA4 Transcription Factor | 1 | 2006 | 21 | 0.060 |
Why?
|
| Superoxide Dismutase | 2 | 2016 | 155 | 0.060 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2022 | 41 | 0.060 |
Why?
|
| Chemokines, CXC | 1 | 2006 | 22 | 0.060 |
Why?
|
| Endothelin-1 | 1 | 2006 | 42 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2006 | 90 | 0.060 |
Why?
|
| Chemokine CXCL10 | 1 | 2006 | 25 | 0.060 |
Why?
|
| Socioeconomic Factors | 2 | 2020 | 663 | 0.060 |
Why?
|
| Probability | 1 | 2007 | 356 | 0.060 |
Why?
|
| Tissue Distribution | 1 | 2006 | 290 | 0.060 |
Why?
|
| Adaptor Proteins, Vesicular Transport | 1 | 2006 | 53 | 0.060 |
Why?
|
| Hyperemia | 2 | 2019 | 17 | 0.060 |
Why?
|
| Berberine | 1 | 2006 | 9 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2006 | 77 | 0.060 |
Why?
|
| Myeloid Differentiation Factor 88 | 1 | 2006 | 59 | 0.060 |
Why?
|
| Early Growth Response Protein 1 | 1 | 2006 | 58 | 0.060 |
Why?
|
| Receptors, Angiotensin | 1 | 2005 | 11 | 0.060 |
Why?
|
| Ovalbumin | 2 | 2017 | 105 | 0.060 |
Why?
|
| Basilar Artery | 1 | 2005 | 42 | 0.060 |
Why?
|
| Losartan | 3 | 2011 | 29 | 0.060 |
Why?
|
| Quaternary Ammonium Compounds | 1 | 2005 | 82 | 0.060 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1013 | 0.060 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2006 | 125 | 0.060 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2011 | 46 | 0.060 |
Why?
|
| Focal Adhesions | 1 | 2026 | 67 | 0.060 |
Why?
|
| Embryo Loss | 1 | 2005 | 5 | 0.060 |
Why?
|
| Haploinsufficiency | 2 | 2018 | 72 | 0.060 |
Why?
|
| Somites | 1 | 2005 | 19 | 0.060 |
Why?
|
| Soluble Guanylyl Cyclase | 1 | 2024 | 4 | 0.050 |
Why?
|
| Global Health | 1 | 2006 | 215 | 0.050 |
Why?
|
| Amino Acid Sequence | 3 | 2008 | 2005 | 0.050 |
Why?
|
| Lactams, Macrocyclic | 1 | 2004 | 15 | 0.050 |
Why?
|
| Benzoquinones | 1 | 2004 | 27 | 0.050 |
Why?
|
| Neural Tube Defects | 1 | 2005 | 39 | 0.050 |
Why?
|
| Demography | 2 | 2016 | 193 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2005 | 220 | 0.050 |
Why?
|
| Triiodothyronine | 1 | 2006 | 367 | 0.050 |
Why?
|
| Monomeric GTP-Binding Proteins | 1 | 2004 | 18 | 0.050 |
Why?
|
| Myocardial Ischemia | 2 | 2003 | 142 | 0.050 |
Why?
|
| Acute Disease | 2 | 2017 | 860 | 0.050 |
Why?
|
| Collateral Circulation | 1 | 2004 | 37 | 0.050 |
Why?
|
| Protein Kinase C | 1 | 2005 | 267 | 0.050 |
Why?
|
| Hydroxyeicosatetraenoic Acids | 2 | 2004 | 5 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2005 | 839 | 0.050 |
Why?
|
| Tyrosine | 1 | 2004 | 135 | 0.050 |
Why?
|
| Vascular Patency | 1 | 2004 | 123 | 0.050 |
Why?
|
| Sesquiterpenes | 2 | 2006 | 13 | 0.050 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1110 | 0.050 |
Why?
|
| Chicago | 2 | 2019 | 1513 | 0.050 |
Why?
|
| Sex Factors | 1 | 2007 | 1138 | 0.050 |
Why?
|
| Incidence | 2 | 2020 | 1779 | 0.050 |
Why?
|
| Evaluation Studies as Topic | 1 | 2003 | 244 | 0.050 |
Why?
|
| Cardiomyopathies | 2 | 2004 | 315 | 0.050 |
Why?
|
| Cross-Over Studies | 3 | 2013 | 409 | 0.050 |
Why?
|
| Quinoxalines | 1 | 2003 | 51 | 0.050 |
Why?
|
| Oxadiazoles | 1 | 2003 | 40 | 0.050 |
Why?
|
| Placenta | 1 | 2005 | 203 | 0.050 |
Why?
|
| Lung Neoplasms | 1 | 2016 | 2457 | 0.050 |
Why?
|
| Virulence Factors, Bordetella | 2 | 1993 | 25 | 0.050 |
Why?
|
| Pertussis Toxin | 2 | 1993 | 31 | 0.050 |
Why?
|
| Antigen-Presenting Cells | 1 | 2004 | 146 | 0.050 |
Why?
|
| Capillaries | 1 | 2003 | 86 | 0.050 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2004 | 174 | 0.050 |
Why?
|
| Molecular Structure | 1 | 2003 | 305 | 0.050 |
Why?
|
| Fibrinolysis | 1 | 2003 | 35 | 0.050 |
Why?
|
| Vasoconstrictor Agents | 1 | 2003 | 80 | 0.050 |
Why?
|
| Gene Expression Profiling | 1 | 2009 | 1565 | 0.050 |
Why?
|
| Gene Transfer Techniques | 1 | 2003 | 155 | 0.050 |
Why?
|
| Chromatography | 1 | 2002 | 25 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2003 | 88 | 0.050 |
Why?
|
| Second Messenger Systems | 1 | 2002 | 39 | 0.050 |
Why?
|
| Calcimycin | 1 | 2002 | 32 | 0.050 |
Why?
|
| Ionophores | 1 | 2002 | 14 | 0.050 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 2002 | 33 | 0.050 |
Why?
|
| Heart Septum | 1 | 2002 | 45 | 0.050 |
Why?
|
| Dichlororibofuranosylbenzimidazole | 1 | 2002 | 4 | 0.050 |
Why?
|
| Young Adult | 3 | 2025 | 7507 | 0.050 |
Why?
|
| Abdominal Muscles | 1 | 2002 | 26 | 0.050 |
Why?
|
| Heart Septal Defects, Ventricular | 1 | 2002 | 66 | 0.050 |
Why?
|
| I-kappa B Kinase | 2 | 1999 | 42 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme Inhibitors | 1 | 2002 | 9 | 0.050 |
Why?
|
| Clotrimazole | 1 | 2002 | 3 | 0.050 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 31 | 0.050 |
Why?
|
| HLA-DR alpha-Chains | 1 | 2002 | 4 | 0.050 |
Why?
|
| Lipoproteins | 1 | 2003 | 136 | 0.050 |
Why?
|
| omega-N-Methylarginine | 1 | 2002 | 17 | 0.050 |
Why?
|
| Cytoprotection | 1 | 2002 | 51 | 0.050 |
Why?
|
| Polymerase Chain Reaction | 2 | 2002 | 895 | 0.050 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2002 | 34 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2002 | 29 | 0.050 |
Why?
|
| HLA-DR Antigens | 1 | 2002 | 58 | 0.050 |
Why?
|
| Potassium Chloride | 1 | 2002 | 75 | 0.050 |
Why?
|
| Age Factors | 1 | 2007 | 1962 | 0.050 |
Why?
|
| Cell Line, Tumor | 3 | 2016 | 2888 | 0.050 |
Why?
|
| Glutathione Transferase | 1 | 2002 | 116 | 0.050 |
Why?
|
| Adenoviridae | 1 | 2003 | 340 | 0.050 |
Why?
|
| RNA Polymerase II | 1 | 2002 | 63 | 0.040 |
Why?
|
| Myosin-Light-Chain Kinase | 2 | 2013 | 41 | 0.040 |
Why?
|
| Mice, Inbred Strains | 4 | 2005 | 281 | 0.040 |
Why?
|
| Meta-Analysis as Topic | 1 | 2002 | 86 | 0.040 |
Why?
|
| Cell Membrane | 2 | 2002 | 673 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2002 | 191 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2001 | 15 | 0.040 |
Why?
|
| Myocardial Contraction | 1 | 2002 | 193 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2002 | 119 | 0.040 |
Why?
|
| Feedback | 2 | 2000 | 132 | 0.040 |
Why?
|
| Radiation Chimera | 2 | 2012 | 22 | 0.040 |
Why?
|
| Acetylcholine | 3 | 2007 | 158 | 0.040 |
Why?
|
| Mental Health | 1 | 2003 | 219 | 0.040 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2004 | 246 | 0.040 |
Why?
|
| Atropine Derivatives | 1 | 2001 | 1 | 0.040 |
Why?
|
| Tight Junction Proteins | 1 | 2021 | 14 | 0.040 |
Why?
|
| Interferon-Stimulated Gene Factor 3 | 1 | 2001 | 2 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 2001 | 16 | 0.040 |
Why?
|
| Biological Transport | 2 | 2000 | 401 | 0.040 |
Why?
|
| Indomethacin | 1 | 2000 | 58 | 0.040 |
Why?
|
| Isoflurane | 1 | 2021 | 57 | 0.040 |
Why?
|
| Sterol Regulatory Element Binding Protein 2 | 1 | 2020 | 5 | 0.040 |
Why?
|
| Receptors, LDL | 2 | 2012 | 54 | 0.040 |
Why?
|
| Heart Rate | 1 | 2003 | 534 | 0.040 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 76 | 0.040 |
Why?
|
| Forkhead Box Protein O1 | 1 | 2020 | 30 | 0.040 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2025 | 3606 | 0.040 |
Why?
|
| Retinoblastoma Protein | 1 | 2000 | 68 | 0.040 |
Why?
|
| Adaptation, Physiological | 1 | 2003 | 349 | 0.040 |
Why?
|
| Patient Admission | 1 | 2021 | 123 | 0.040 |
Why?
|
| DNA Primers | 3 | 2011 | 530 | 0.040 |
Why?
|
| Pregnancy | 2 | 2021 | 3244 | 0.040 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 1999 | 9 | 0.040 |
Why?
|
| Tunica Media | 1 | 1999 | 16 | 0.040 |
Why?
|
| Radioligand Assay | 2 | 2005 | 32 | 0.040 |
Why?
|
| Pulse Wave Analysis | 1 | 2019 | 9 | 0.040 |
Why?
|
| Endothelial Growth Factors | 1 | 1999 | 55 | 0.040 |
Why?
|
| Lymphokines | 1 | 1999 | 74 | 0.040 |
Why?
|
| Adolescent | 2 | 2025 | 10080 | 0.040 |
Why?
|
| Epithelial Cells | 2 | 2018 | 709 | 0.040 |
Why?
|
| Metalloendopeptidases | 1 | 1999 | 44 | 0.040 |
Why?
|
| Renin | 1 | 2019 | 69 | 0.040 |
Why?
|
| Cytoskeleton | 1 | 2000 | 200 | 0.040 |
Why?
|
| GTPase-Activating Proteins | 1 | 1999 | 71 | 0.040 |
Why?
|
| Microvessels | 1 | 2019 | 70 | 0.040 |
Why?
|
| Echocardiography | 1 | 2003 | 783 | 0.040 |
Why?
|
| rhoB GTP-Binding Protein | 1 | 1998 | 3 | 0.040 |
Why?
|
| Guanosine 5'-O-(3-Thiotriphosphate) | 1 | 1998 | 11 | 0.040 |
Why?
|
| Adenylyl Cyclases | 1 | 1999 | 105 | 0.040 |
Why?
|
| Illinois | 1 | 2020 | 522 | 0.040 |
Why?
|
| ADP Ribose Transferases | 1 | 1998 | 7 | 0.040 |
Why?
|
| Cytotoxins | 1 | 1998 | 18 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 1998 | 83 | 0.040 |
Why?
|
| Diterpenes | 1 | 1998 | 24 | 0.030 |
Why?
|
| X-Ray Microtomography | 1 | 2019 | 108 | 0.030 |
Why?
|
| Densitometry | 1 | 1997 | 23 | 0.030 |
Why?
|
| Transcription Factor RelA | 1 | 1997 | 39 | 0.030 |
Why?
|
| Bacterial Toxins | 1 | 1998 | 113 | 0.030 |
Why?
|
| Bleomycin | 1 | 2018 | 102 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2019 | 674 | 0.030 |
Why?
|
| Dogs | 2 | 2012 | 639 | 0.030 |
Why?
|
| Onium Compounds | 1 | 1997 | 5 | 0.030 |
Why?
|
| Platelet Activation | 1 | 2017 | 18 | 0.030 |
Why?
|
| Catalase | 1 | 1997 | 46 | 0.030 |
Why?
|
| Myofibroblasts | 1 | 2018 | 51 | 0.030 |
Why?
|
| Biphenyl Compounds | 1 | 1997 | 63 | 0.030 |
Why?
|
| Organizational Case Studies | 1 | 2017 | 26 | 0.030 |
Why?
|
| Cost Control | 1 | 2017 | 44 | 0.030 |
Why?
|
| Oxidoreductases | 1 | 1997 | 112 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2017 | 8 | 0.030 |
Why?
|
| Urban Health | 1 | 2017 | 54 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 1998 | 1028 | 0.030 |
Why?
|
| Immunohistochemistry | 2 | 2011 | 1815 | 0.030 |
Why?
|
| Hypoxia, Brain | 2 | 2007 | 41 | 0.030 |
Why?
|
| Bone Morphogenetic Protein Receptors, Type II | 1 | 2016 | 17 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 174 | 0.030 |
Why?
|
| Smad Proteins | 1 | 2016 | 42 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2019 | 461 | 0.030 |
Why?
|
| Respiratory Mucosa | 1 | 2017 | 91 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 213 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2019 | 977 | 0.030 |
Why?
|
| Ligands | 1 | 1997 | 486 | 0.030 |
Why?
|
| Aerobiosis | 1 | 1995 | 21 | 0.030 |
Why?
|
| Nitrites | 1 | 1995 | 34 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2002 | 2529 | 0.030 |
Why?
|
| Molsidomine | 1 | 1995 | 7 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2019 | 1284 | 0.030 |
Why?
|
| Proteoglycans | 1 | 2015 | 76 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 131 | 0.030 |
Why?
|
| Vesicular Transport Proteins | 1 | 2015 | 71 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 198 | 0.030 |
Why?
|
| Drug Combinations | 1 | 2015 | 201 | 0.030 |
Why?
|
| Laminin | 1 | 2015 | 89 | 0.030 |
Why?
|
| Mast Cells | 1 | 2015 | 97 | 0.030 |
Why?
|
| Metformin | 1 | 2016 | 132 | 0.030 |
Why?
|
| Immunoglobulin E | 1 | 2015 | 156 | 0.030 |
Why?
|
| Th2 Cells | 1 | 2015 | 152 | 0.030 |
Why?
|
| Cisplatin | 1 | 2016 | 578 | 0.030 |
Why?
|
| Allergens | 1 | 2015 | 196 | 0.030 |
Why?
|
| Patient Discharge | 1 | 2017 | 381 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 2 | 2006 | 68 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2017 | 418 | 0.020 |
Why?
|
| Collagen | 1 | 2015 | 313 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2013 | 44 | 0.020 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2013 | 14 | 0.020 |
Why?
|
| Penile Erection | 1 | 2013 | 22 | 0.020 |
Why?
|
| Genetic Association Studies | 1 | 2014 | 310 | 0.020 |
Why?
|
| gamma Catenin | 1 | 2012 | 7 | 0.020 |
Why?
|
| Keratin-14 | 1 | 2012 | 5 | 0.020 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2013 | 71 | 0.020 |
Why?
|
| Desmosomes | 1 | 2012 | 11 | 0.020 |
Why?
|
| Catenins | 1 | 2012 | 13 | 0.020 |
Why?
|
| ATP Binding Cassette Transporter 1 | 1 | 2012 | 10 | 0.020 |
Why?
|
| Liver X Receptors | 1 | 2012 | 22 | 0.020 |
Why?
|
| Foam Cells | 1 | 2012 | 18 | 0.020 |
Why?
|
| Cholesterol, Dietary | 1 | 2012 | 27 | 0.020 |
Why?
|
| Orphan Nuclear Receptors | 1 | 2012 | 20 | 0.020 |
Why?
|
| Immunoglobulin G | 1 | 2015 | 480 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 985 | 0.020 |
Why?
|
| Hair | 1 | 2012 | 56 | 0.020 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2012 | 70 | 0.020 |
Why?
|
| Integrases | 1 | 2012 | 68 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2013 | 340 | 0.020 |
Why?
|
| Epidermis | 1 | 2012 | 106 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2013 | 340 | 0.020 |
Why?
|
| Rats, Inbred Strains | 1 | 1992 | 300 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2013 | 256 | 0.020 |
Why?
|
| Nifedipine | 1 | 2011 | 24 | 0.020 |
Why?
|
| Cytoskeletal Proteins | 1 | 2013 | 225 | 0.020 |
Why?
|
| PPAR gamma | 1 | 2012 | 80 | 0.020 |
Why?
|
| Biological Assay | 1 | 1992 | 82 | 0.020 |
Why?
|
| RNA Interference | 1 | 2013 | 388 | 0.020 |
Why?
|
| ATP-Binding Cassette Transporters | 1 | 2012 | 144 | 0.020 |
Why?
|
| Radionuclide Ventriculography | 1 | 1991 | 3 | 0.020 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2013 | 207 | 0.020 |
Why?
|
| Linear Models | 1 | 2013 | 424 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Pulsed | 1 | 2011 | 5 | 0.020 |
Why?
|
| Arterial Occlusive Diseases | 2 | 2004 | 107 | 0.020 |
Why?
|
| Dyspnea | 1 | 2012 | 90 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2011 | 36 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 903 | 0.020 |
Why?
|
| Plethysmography | 1 | 1991 | 16 | 0.020 |
Why?
|
| P-Selectin | 2 | 2002 | 14 | 0.020 |
Why?
|
| Gene Knock-In Techniques | 1 | 2011 | 31 | 0.020 |
Why?
|
| DNA Mutational Analysis | 2 | 2004 | 548 | 0.020 |
Why?
|
| Huntingtin Protein | 1 | 2011 | 12 | 0.020 |
Why?
|
| Amlodipine | 1 | 2011 | 5 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2011 | 120 | 0.020 |
Why?
|
| Blood Circulation | 1 | 2011 | 29 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 238 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2013 | 556 | 0.020 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2010 | 30 | 0.020 |
Why?
|
| Receptors, Lysosphingolipid | 1 | 2010 | 38 | 0.020 |
Why?
|
| ROC Curve | 1 | 2013 | 794 | 0.020 |
Why?
|
| Muscles | 1 | 1991 | 179 | 0.020 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2010 | 40 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2011 | 211 | 0.020 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2010 | 42 | 0.020 |
Why?
|
| Leg | 1 | 1991 | 145 | 0.020 |
Why?
|
| Adenine | 1 | 2011 | 101 | 0.020 |
Why?
|
| Rabbits | 1 | 2011 | 581 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2011 | 578 | 0.020 |
Why?
|
| Adenosine Triphosphate | 1 | 2011 | 319 | 0.020 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 62 | 0.020 |
Why?
|
| MicroRNAs | 1 | 2014 | 604 | 0.020 |
Why?
|
| Logistic Models | 1 | 2013 | 1275 | 0.020 |
Why?
|
| E-Selectin | 2 | 1999 | 31 | 0.020 |
Why?
|
| Plaque, Amyloid | 1 | 2009 | 69 | 0.020 |
Why?
|
| Receptor, Bradykinin B1 | 1 | 2008 | 4 | 0.020 |
Why?
|
| Autoimmunity | 1 | 2010 | 195 | 0.020 |
Why?
|
| Microscopy, Fluorescence | 1 | 2010 | 435 | 0.020 |
Why?
|
| Electrocardiography | 1 | 1991 | 527 | 0.020 |
Why?
|
| Placebos | 1 | 2008 | 209 | 0.020 |
Why?
|
| Reproducibility of Results | 1 | 2014 | 2784 | 0.020 |
Why?
|
| Neoplasms | 1 | 2004 | 3334 | 0.020 |
Why?
|
| Hypertrophy, Left Ventricular | 1 | 2008 | 63 | 0.020 |
Why?
|
| Melanoma | 1 | 2013 | 524 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2010 | 1110 | 0.020 |
Why?
|
| Keratinocytes | 1 | 2008 | 156 | 0.020 |
Why?
|
| Cell Separation | 1 | 2008 | 200 | 0.020 |
Why?
|
| Mice, Inbred ICR | 1 | 2007 | 76 | 0.020 |
Why?
|
| Neuroglia | 1 | 2007 | 78 | 0.020 |
Why?
|
| Lysophospholipids | 1 | 2007 | 67 | 0.020 |
Why?
|
| Forearm | 1 | 2007 | 33 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 306 | 0.020 |
Why?
|
| Stimulation, Chemical | 1 | 2006 | 54 | 0.020 |
Why?
|
| KB Cells | 1 | 2006 | 2 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2008 | 720 | 0.010 |
Why?
|
| Angiotensin II Type 2 Receptor Blockers | 1 | 2005 | 2 | 0.010 |
Why?
|
| Nitroarginine | 1 | 2005 | 16 | 0.010 |
Why?
|
| Diet | 1 | 2009 | 469 | 0.010 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2005 | 8 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-fos | 1 | 2006 | 66 | 0.010 |
Why?
|
| Protein Biosynthesis | 1 | 2008 | 393 | 0.010 |
Why?
|
| Indicators and Reagents | 1 | 2005 | 68 | 0.010 |
Why?
|
| Drugs, Chinese Herbal | 1 | 2006 | 72 | 0.010 |
Why?
|
| Imidazoles | 1 | 2005 | 141 | 0.010 |
Why?
|
| Intracranial Embolism | 1 | 2005 | 29 | 0.010 |
Why?
|
| Lipids | 1 | 2006 | 293 | 0.010 |
Why?
|
| Sp1 Transcription Factor | 1 | 2004 | 24 | 0.010 |
Why?
|
| Aorta, Thoracic | 1 | 2006 | 154 | 0.010 |
Why?
|
| Germany | 1 | 2004 | 84 | 0.010 |
Why?
|
| Arachidonic Acid | 1 | 2004 | 63 | 0.010 |
Why?
|
| Tibial Arteries | 1 | 2004 | 5 | 0.010 |
Why?
|
| 3' Untranslated Regions | 1 | 2004 | 102 | 0.010 |
Why?
|
| Boston | 1 | 2004 | 42 | 0.010 |
Why?
|
| Nutritional Physiological Phenomena | 1 | 2004 | 27 | 0.010 |
Why?
|
| Popliteal Artery | 1 | 2004 | 32 | 0.010 |
Why?
|
| Time | 1 | 2004 | 80 | 0.010 |
Why?
|
| Gonadal Steroid Hormones | 1 | 2004 | 50 | 0.010 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 2004 | 30 | 0.010 |
Why?
|
| Swine | 1 | 2005 | 592 | 0.010 |
Why?
|
| Veratrine | 1 | 2003 | 1 | 0.010 |
Why?
|
| Amino Acid Substitution | 1 | 2004 | 334 | 0.010 |
Why?
|
| Introns | 1 | 2004 | 301 | 0.010 |
Why?
|
| Hostility | 1 | 2003 | 28 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2004 | 230 | 0.010 |
Why?
|
| Cricetinae | 1 | 2004 | 533 | 0.010 |
Why?
|
| Lower Extremity | 1 | 2004 | 108 | 0.010 |
Why?
|
| Risk | 1 | 2004 | 660 | 0.010 |
Why?
|
| Exons | 1 | 2004 | 451 | 0.010 |
Why?
|
| Cardiac Pacing, Artificial | 1 | 2003 | 116 | 0.010 |
Why?
|
| Failure to Thrive | 1 | 2002 | 17 | 0.010 |
Why?
|
| Oxygen Consumption | 1 | 2003 | 239 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2002 | 72 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 276 | 0.010 |
Why?
|
| Motor Activity | 1 | 2004 | 328 | 0.010 |
Why?
|
| Psychometrics | 1 | 2003 | 356 | 0.010 |
Why?
|
| Calcinosis | 1 | 2002 | 220 | 0.010 |
Why?
|
| Blood Gas Analysis | 1 | 2001 | 35 | 0.010 |
Why?
|
| Morphogenesis | 1 | 2002 | 207 | 0.010 |
Why?
|
| Reoperation | 1 | 2004 | 727 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2004 | 911 | 0.010 |
Why?
|
| Skin | 1 | 2004 | 591 | 0.010 |
Why?
|
| Survival Analysis | 1 | 2004 | 1527 | 0.010 |
Why?
|
| Cytochalasin D | 1 | 2000 | 15 | 0.010 |
Why?
|
| GATA2 Transcription Factor | 1 | 2000 | 16 | 0.010 |
Why?
|
| Anxiety | 1 | 2003 | 370 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2004 | 1751 | 0.010 |
Why?
|
| Genetic Testing | 1 | 2004 | 594 | 0.010 |
Why?
|
| Cerebral Arteries | 1 | 2000 | 75 | 0.010 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 1999 | 54 | 0.010 |
Why?
|
| Matrix Metalloproteinases, Membrane-Associated | 1 | 1999 | 4 | 0.010 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 1999 | 69 | 0.010 |
Why?
|
| Gelatinases | 1 | 1999 | 10 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 1999 | 48 | 0.010 |
Why?
|
| Immunoenzyme Techniques | 1 | 1999 | 291 | 0.010 |
Why?
|
| Depression | 1 | 2003 | 617 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2003 | 3212 | 0.010 |
Why?
|